Prof Sir Alasdair Breckenridge CBE FRSE

Member of Scientific Advisory Board

Alasdair Breckenridge was Chairman of the Medicines and Healthcare products Regulatory Agency which was formed in April 2003 by the merger of the Medicines Control Agency and the Medical Devices Agency.  Previously he was Chairman of the Committee on Safety of Medicines and Professor of Clinical Pharmacology in the University of Liverpool. He is now Chairman of the Advisory Board of the Centre of Regulatory Excellence of Duke/NUS in Singapore. He was knighted in 2004. 

During his tenure at MHRA, Sir Alasdair served as the first Chair of the Department of Health’s Emerging Science and Bioethics Advisory Committee (ESBAC), an organisation responsible for providing advice to UK health departments on emerging healthcare scientific developments and their ethical, legal, social and economic implications. He was a member of the Medical Research Council and he worked closely on several programmes of the European Union, the World Health Organisation and the International Union of Pharmacology and as Chair of the Committee on Safety of Medicines.


As a regulator, I am intrigued by the possible use of a drug with a previously uncertain reputation in a novel situation and how the regulatory hurdles could be overcome. To take a drug from the 1950s and reposition it in modern medicine especially for an unmet medical need presents a series of fascinating challenges.